Autem Therapeutics (https://www.autemtherapeutics.com/) is an emerging oncology therapeutic and bioelectric technology company that is developing a novel systemic treatment platform for multiple cancer types that shrinks tumors (ORR, PFS, DCR), extends survival (mOS of 11.5 months), and improves quality of life (QoL of 14+ months TTD). The Company was granted at an FDA Breakthrough Therapy designation and is headquartered in Hanover, NH, USA.

Zentynel Frontier Investments is a venture capital investment firm based in Santiago, Chile. The firm seeks to invest in companies operating in the life sciences, healthcare, biofuels and other artificial intelligence-enabled technology sectors.

Follow-on investments made by Zentynel and Spectra Investments, a venture capital firm based in Sao Paolo, Brazil

The transaction provides Autem with funds to complete the Company’s next generation EMsys™ System and related testing and validation, the US FDA Investigational Device Exemption (IDE) and European and Latin American regulatory submissions/approvals, and the start-up phase of its HCC pivotal trial and operations through CY 2023.

Cypress Associates LLC acted as placement agent of the equity and financial advisor to Autem Medical.